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• Registry-based studies indicate a link between arterial- and venous thromboembolism 
(VTE) 
• We studied this association in a cohort with confounder information and validated 
outcomes 
• Myocardial infarction (MI) was associated with a 4.8-fold increased short-term risk of VTE 






Background: Recent studies have demonstrated an association between venous 
thromboembolism (VTE) and arterial thrombotic diseases.  
 
Objectives: We aimed to study the association between incident myocardial infarction (MI) and 
VTE in a prospective population-based cohort. 
 
Methods: Study participants (n=29 506) were recruited from three surveys of the Tromsø Study 
(conducted in 1994-95, 2001-02 and 2007-08) and followed through 2010. All incident events of 
MI and VTE during follow-up were recorded. Cox-regression models with age as time scale and 
MI as a time-dependent variable were used to calculate hazard ratios (HR) of VTE adjusted for 
sex, BMI, blood pressure, diabetes mellitus, HDL-cholesterol, smoking, physical activity and 
education level. 
 
Results: During a median follow-up of 15.7 years, 1 853 participants experienced a MI and 699 
experienced a VTE. MI was associated with a 51% increased risk of VTE (HR 1.51; 95% CI 
1.08-2.10) and a 72% increased risk of pulmonary embolism (PE) (HR 1.72; 95% CI 1.07-2.75), 
but not significantly associated with risk of deep vein thrombosis (DVT) (HR 1.36, 95% CI, 0.86-
2.15). The highest risk estimates for PE were observed during the first sixth months after the MI 
(HR 8.49; 95% CI 4.00-18.77). MI explained 6.2% of the PEs in the population (population 
attributable risk) and 78.5% of the PE risk in MI-patients (attributable risk).  
 
Conclusions: Our findings indicate that MI is associated with a transient increased risk of VTE 













Despite definite differences in pathology and treatment strategies, growing evidence suggests a 
bidirectional relation between venous thromboembolism (VTE) (deep vein thrombosis [DVT] and 
pulmonary embolism [PE]) and arterial thromboembolic diseases (ATD) (myocardial infarction 
[MI] and ischemic stroke) [1-4]. The interrelation between ATD and VTE could be attributed to 
shared risk factors such as obesity, smoking or family history of myocardial infarction, indirect 
causal factors like hospitalizations accompanied by periods of immobilization, or a direct causal 
relation such as transient prothrombotic response secondary to sudden tissue damage and 
venous stasis following heart failure [5].   
Results from prospective cohorts, applying cause-specific regression models, have 
revealed that among the traditional atherosclerotic risk factors, only age, obesity and familial 
predisposition for MI are shared risk factors for ATD and VTE [6-9]. In a case-control study, 
patients with unprovoked VTE were reported to have a higher frequency of carotid plaques than 
control participants [2]. Conversely, subsequent large population-based cohort studies have 
failed to confirm an association between carotid atherosclerosis and VTE [10-12], indicating that 
atherosclerosis is not a shared risk factor for ATD and VTE.   
Population-based registry studies have shown that patients with a history of MI are at 
increased short-term risk of subsequent VTE [13, 14]. However, results from registry-based 
linkage studies should be interpreted with caution as they often lack information about 
confounders and have limited validation of exposure and outcomes. For instance, an evaluation 
of the Danish National Patient Registry revealed that the positive predictive values (PPV) for 
VTE diagnoses from emergency departments and hospitals were only 44% and 67-77%, 
respectively [15]. Moreover, lack of important clinical information, such as body mass index 
(BMI), has limited the ability to adjust for confounding in previous registry-based studies [13, 14]. 
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We therefore aimed to investigate the association between MI and future risk of VTE in a 
population-based cohort with validated information on exposure (MI), endpoint (VTE), and 
potential confounders.   
Materials and Methods 
Study Population 
The Tromsø Study is a single-center, prospective, population-based study, with repeated health 
surveys of the inhabitants of Tromsø, Norway. Study participants were recruited from the fourth, 
fifth and sixth survey of the Tromsø Study, conducted in 1994-95, 2001-02 and 2007-08, 
respectively. The overall attendance rates were high; 77% in the fourth, 78% in the fifth and 66% 
in the sixth survey. A detailed description of the Tromsø study has been published elsewhere 
[16]. In total, 30 586 unique participants aged 25 to 97 years participated in at least one of the 
surveys, and of these, 21 529 participants participated in two or all three surveys. Participants 
who did not consent to medical research (n=225), participants not officially registered as 
inhabitants of the municipality of Tromsø at the date of study enrollment (n=48), and participants 
with a previous history of VTE (n=78) or MI (n=729) before baseline were excluded. 
Consequently, 29 506 participants were included in the study, and followed from the date of 
enrollment to the end of follow up, 31st of December 2010 (Fig. 1). The regional committee for 
medical and health research ethics in North Norway approved the study, and all participants 
gave their informed written consent. 
Baseline measurements 
Information about study participants was collected by physical examinations, blood samples and 
self-administrated questionnaires at each survey. Systolic and diastolic blood pressures were 
measured three times with 1 minute intervals with an automatic device (Dinamap Vital Signs 
Monitor, 1846; Critikon Inc., Tampa, FL, USA) in a sitting position after 2 minutes of rest, and 
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defined as the mean of the last two readings. Non-fasting blood samples were collected from an 
antecubital vein, serum prepared by centrifugation after 1-hour respite at room temperature and 
analyzed at the Department of Clinical Chemistry, University Hospital of North Norway, Tromsø, 
Norway. Serum total cholesterol was analyzed by an enzymatic colorimetric method using a 
commercially available kit (CHOD-PAP, Boehringer-Mannheim, Mannheim, Germany). Serum 
HDL-cholesterol was measured after precipitation of lower-density lipoproteins with heparin and 
manganese chloride. Height and weight were measured with participants wearing light clothes 
and no shoes. BMI was calculated as weight in kilograms divided by the square of height in 
meters (kg/m2). Obesity (BMI ≥30 kg/m2) was classified according to the World Health 
Organization definition [17]. Hypertension was classified as mean systolic blood pressure ≥140 
mm Hg, mean diastolic blood pressure ≥90 mm Hg, or self-reported use of blood pressure-
lowering drugs. Hypercholesterolemia was classified as total serum cholesterol ≥6.5 mmol/L or 
self-reported use of lipid lowering drugs. Information on family history of MI, diabetes mellitus, 
physical activity and education level was collected from a self-administrated questionnaire. 
Assessment of MI 
Adjudication of hospitalized and out-of hospital MI events was performed by an independent 
endpoint committee and based on data from hospital and out-of hospital medical records, 
autopsy records, and death certificates.  The national 11-digit identification number allowed 
linkage to national and local diagnosis registries. Cases of incident MI were identified by linkage 
to the hospital discharge diagnosis registry at the University Hospital of North Norway (UNN) 
searching for ICD-9 codes 410-414 and 430-438 in the time period 1994-98 and thereafter ICD-
10 codes I20-I25, and I60-I69. The hospital medical records were retrieved for case validation. 
Modified WHO MONICA/MORGAM criteria for MI [18] were used and included clinical symptoms 
and signs, findings in electrocardiograms (ECG), values of cardiac biomarkers and autopsy 
reports when applicable.  Further, linkage to the National Causes of Death Registry at Statistics 
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Norway allowed identification of fatal incident MI cases that occurred as out-of-hospital deaths, 
including deaths that occurred outside of Tromsø. Information from the death certificates was 
used to collect relevant information on the MI events from additional sources such as autopsy 
reports and records from nursing homes, ambulance services and general practitioners. 
 
Registry of VTE 
All incident VTE events during follow-up were identified by searching the hospital discharge 
diagnosis registry, the autopsy registry and the radiology procedure registry at the University 
Hospital of North Norway as previously described [19]. The University Hospital of North Norway 
is the only hospital in the region, and all diagnostic radiology and hospital care is provided 
exclusively by this hospital. The medical record for each potential case of VTE was reviewed by 
trained personnel, and a VTE event was considered verified and recorded when presence of 
clinical signs and symptoms of DVT or PE were combined with objective confirmatory tests (i.e. 
compression ultrasonography, venography, spiral computed tomography, perfusion-ventilation 
scan, pulmonary angiography or autopsy), and resulted in a VTE diagnosis that required 
treatment, as previously described in detail [19]. VTE cases from the autopsy registry were 
recorded when the death certificate indicated VTE as cause of death or a significant condition 
associated with death. The VTE events were classified as provoked or unprovoked depending 
on the presence of provoking factors at the time of diagnosis. Provoking factors included recent 
surgery or trauma within the previous 8 weeks, acute medical conditions (i.e. acute MI, ischemic 
stroke or major infectious diseases), active cancer, immobilization (i.e. bed rest >3 days, 
wheelchair use or long-distance travel exceeding 4 hours within the last 14 days prior to the 





Participants who developed MI during the study period contributed with non-exposed person-
time from the inclusion date to the date of a diagnosis of MI, and then with exposed person-time 
from the date of MI onwards. For each participant, non-exposed and exposed person-years 
were counted from the date of enrollment to the date of an incident diagnosis of VTE, the date 
the participant died or moved from Tromsø, or until the end of the study period, 31st of December 
2010, whichever came first. Participants who died or moved from the municipality during follow-
up were censored at the date of death or migration.  
Statistical analyses were performed using STATA version 14.0 (Stata Corporation, 
College Station, TX, USA). Crude incidence rates (IR) of VTE were calculated and expressed as 
number of events per 1 000 person-years at risk. Cox proportional hazards regression models 
were used to calculate hazard ratios (HR) with 95% confidence intervals (CI) of VTE, DVT and 
PE after MI. Age was used as time scale in the Cox model, with the age of the participants at 
study enrollment defined as entry time and age at the VTE event or censoring event (i.e. death, 
migration, or the date of study end) defined as exit time. MI was included as a time-dependent 
covariate in the Cox model. Therefore, participants who developed MI during follow-up 
contributed with person-years in both the unexposed and exposed group. In those who 
participated in several surveys, information on possible potential confounders was updated at 
each survey. We estimated HRs with three different models. The first model was adjusted for 
age (as time scale) and sex, while the second model was additionally adjusted for BMI. Model 3 
was adjusted for age (as time scale), sex, BMI, diabetes mellitus, smoking, systolic blood 
pressure, HDL-cholesterol, physical activity and education.  
The proportional hazard assumption was tested using Schoenfeld residuals and found 
not violated. Statistical interactions between MI and sex were tested by including cross-product 
terms in the proportional hazards models, and no interactions was found. 
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Attributable risk (AR), the proportion of events among the exposed participants that could 
be explained by the exposure, was calculated from incidence rates of VTE in the MI (Ie) and non-
MI (Io) population and expressed as a percentage (AR=100x(Ie-Io)/Ie)). Population attributable 
risk (PAR), the proportion of events in the population that could be attributed to the exposure, 
was calculated based on incidence rates of VTE in the total population (Ip) and in the non-
exposed population (Io) and expressed as a percentage (PAR= 100x(Ip-Io)/Ip)). GraphPad Prism 
version 6.0 (GraphPad Software, San Diego, CA, USA) was used to generate a figure showing 





There were 1 892 (6.4%) participants who developed a first-time MI and 699 (2.4%) participants 
who developed a first-time VTE during a median 15.7 years of follow-up. Baseline characteristics 
of the study participants with and without MI are shown in Table 1. Participants with MI had 
higher mean age and BMI, and a higher proportion of men, smokers, and participants with 
hypertension than those without MI (Table 1).  
Characteristics of the VTE events are shown in Table 2. Among the 699 VTE events, 405 
(57.9%) were DVTs and 294 (42.1%) were PEs. Moreover, 358 events (51.2%) were classified 
as provoked and 341 events (48.8%) were classified as unprovoked. The most frequent 
provoking factors were active cancer, immobilization, and surgery (Table 2). The proportion of 
PEs was higher among the VTE events that occurred after an MI (53% vs. 41%) compared to 
VTE events that appeared in the absence of a previous MI. Further, surgery was a more 
frequent provoking factor for VTE in participants with prior MI (27%) than in those without MI 
(15%) (Data not shown).  
Incidence rates and hazard ratios of VTE and subtypes of VTE according to MI are 
shown in Table 3. In participants without MI, 652 VTE events were identified during 354 865 
person-years of follow-up (IR 1.8 per 1 000 person-years), whereas there were 47 VTE events 
during 7 062 person-years of follow-up in participants exposed to MI (IR 6.7 per 1 000 person-
years). Overall, subjects with a previous MI had 51% (HR, 1.51; 95% CI, 1.09-2.11) higher risk 
of VTE than subjects without a previous MI in a multivariable model adjusted for traditional 
atherosclerotic risk factors including sex, BMI, systolic blood pressure, diabetes mellitus, HDL-
cholesterol, smoking, physical activity and education level (Table 3). In a subgroup of 
participants with available data on family history of MI (n=21 096), addition of family history of MI 
to the multivariable model did not change the risk estimates for the association between MI and 
VTE (Supplementary Table 1). In separate analyses of PE and DVT after MI, PE displayed 
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higher risk estimates than DVT. The multivariable HR was 1.72 (95% CI, 1.07-2.79) for PE and 
1.36 (95% CI, 0.86-2.15) for DVT (Table 3). 
In analyses stratified by presence of provoking factors, MI was associated with increased 
risk of provoked VTE (multivariable adjusted HR, 1.83; 95% CI, 1.21-2.79) and provoked PE 
(multivariable adjusted HR 2.29; 95% CI, 1.20-4.37), but not with provoked DVT or any 
unprovoked events (Table 4). Among MI-patients, 72.4% of the VTEs could be attributed to the 
MI (attributable risk), and 4.7% of the VTE events in the entire study population could be 
explained by MI (population attributable risk). For PE, the numbers attributed to MI were higher; 
the attributable risk was 78.5%, and the population attributable risk was 6.2%. 
Incidence rates and hazard ratios of VTE were high immediately after the MI and 
declined rapidly thereafter (Table 5 and Figure 2). The incidence rate of VTE was 18 per 1 000 
person-years, and the hazard ratio of VTE was 5-fold higher in participants with compared to 
those without MI during the first 6 months after the incident MI diagnosis (adjusted HR 4.86; 95% 
CI, 2.57-9.05). Following the initial 6 months after the MI, the risk of VTE was not significantly 
increased (Table 5). Separate analysis of PE showed a similar, though augmented, risk pattern. 
The multivariable HR for PE during the first 6 months after MI was 8.49 (95% CI, 4.00-18.17). 
The risk of PE remained almost 4-fold higher from 6 months to 1 year after the MI compared to 
the risk in those without MI (adjusted HR 3.78; 95% CI, 1.20-11.89), but the association 






In our population-based cohort, participants with MI had higher risk of subsequent VTE, and PE 
in particular, compared to participants without MI in analyses adjusted for traditional 
atherosclerotic risk factors. The risk estimates for PE were highest during the first 6 months after 
the MI and declined rapidly thereafter. We found that 78.5% of the PE events among MI-patients 
could be attributed to the MI, whereas 6.2% of the PEs in the population could be attributed to 
MI. 
Previous studies have indicated an association between MI and increased risk of future 
VTE. In a meta-analysis of placebo-controlled trials evaluating the effect of antithrombotic drugs, 
4% of patients with MI had a symptomatic PE during the first two weeks after the MI event.[20] A 
relation between MI and PE was further supported in a cross-sectional study where an 
association between coronary heart disease and PE was found in patients aged 60 years or 
older.[21] In agreement with our findings, Sørensen and colleagues found that the risk of VTE, 
and PE in particular, was higher in the first months immediately after a MI when compared with 
the VTE risk in population-based controls in two registry-based case-control studies [13, 14]. 
The explanations for the observed association between MI and future risk of VTE are yet 
unknown. Potential mechanisms include shared risk factors, indirect factors, or a direct causal 
relationship [5]. If the association between MI and VTE is due to shared cardiovascular risk 
factors, the cardiovascular risk factors work as confounding factors by increasing the risk of both 
MI and VTE. In agreement with this, cohort studies conducting cause-specific analyses have 
revealed age, obesity and family history of MI as shared risk factors for MI and VTE [6-9]. 
Conversely, our findings argue against a strong impact of shared risk factors on the association 
between MI and future risk of VTE. First, shared risk factors would mediate a permanent and not 
a transient VTE risk as observed in our study.  Second, adjustments for atherosclerotic risk 
factors, such as obesity and family history of MI, would substantially attenuate the association 
between MI and subsequent VTE if the risk factors were actual confounders. In our study, 
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adjustments for atherosclerotic risk factors had marginal impact on the risk estimates for the 
association between MI and VTE. However, our findings do not exclude the possibility of joint 
effects between shared inherited prothrombotic risk factors that would augment the VTE risk 
under circumstances of high thrombosis risk related to the MI itself (e.g. hospitalizations 
accompanied by periods of immobilization, transient prothrombotic response secondary to 
sudden tissue damage, and venous stasis following heart failure) [22, 23]. Furthermore, several 
other risk factors for VTE, including high levels of coagulation factors VIII, IX, and XI, 
plasminogen activator inhibitor-1 and von Willebrand factor, have also been shown as risk 
factors for arterial cardiovascular disease [24, 25], and increase immediately after MI, and may 
therefore mediate the transient VTE risk after MI observed in our study. 
The transient increase in VTE risk after MI points towards causal mechanisms related to 
the MI itself.  Patients with MI are hospitalized and temporarily immobilized, which both are 
strong predisposing factors for VTE [26]. Previous studies have suggested that hospitalization 
after MI partly explains the observed association between MI and subsequent VTE [13, 27]. This 
suggestion was supported by the short-term nature of risk [13] and the attenuation of risk 
estimates after adjusting for hospitalization due to surgery or acute medical illness as well as 
nursing home confinement [27]. Accordingly, we observed a transient short-term risk of VTE 
after MI and stratified analyses revealed higher risk estimates for provoked compared to 
unprovoked events. In agreement with previous observations [13, 14, 27], our findings support 
the notion that indirect causal factors, such as hospitalization and subsequent immobilization as 
well as coronary artery bypass surgery or endovascular procedures after MI, may contribute 
substantially to the observed association between MI and VTE.  
A direct causal relation between MI and VTE may also contribute to VTE risk in MI 
patients. Local disturbances in the cardiopulmonary circulation after MI may predispose for 
thrombus formation by stasis in the pulmonary circulation due to backward failure secondary to 
left ventricular dysfunction [28, 29], by injury of the vascular endothelium [30], or by activation of 
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the coagulation system during the acute phase of MI [31]. Atrial fibrillation is a frequent 
complication after MI [32]. Recently, we reported that atrial fibrillation was associated with 
increased risk of VTE, and PE in particular [33]. According to the transient nature of VTE risk 
and the particularly high risk of PE observed in our study, it is likely to assume that direct causal 
mechanism(s) secondary to local disturbances in the cardiopulmonary circulation or electro-
mechanical activity (e.g. atrial fibrillation) may convey parts of the VTE risk after MI. Previous 
studies have shown that DVT can be identified in only 50% of patients with PE, [34] which 
supports the concept that pulmonary thrombi may form de novo in the lungs or origin from other 
sources of emboli. Alternatively, the high PE rather than DVT risk after MI may be explained by 
detection bias since patients with previous MI are more likely to undergo examinations for chest 
pain.  
Our findings may have some clinical implications. In our population-based cohort, 6.2 % 
of PE events could be attributed to MI exposure, and 78% of the VTE events among the MI 
patients were attributable to the MI itself. These numbers may actually be an underestimation 
due to concomitant use of drugs (aspirin, heparins, and statins) in MI, which is known to reduce 
the VTE risk. The high amount of PE explained by exposure to MI may suggest that 
anticoagulant treatment of MI patients would prevent several subsequent PE events.  
Randomized clinical trials have shown that prolonged oral anticoagulant treatment with vitamin K 
antagonists (VKA) is equal to (Waris II trial) [35] or superior to (ASPECT II trial) [36] antiplatelet 
treatment for recurrent MI. Unfortunately, none of these studies have reported VTE as a 
secondary endpoint. Furthermore, VKA and non-vitamin K oral anticoagulants (NOACs) have 
been shown to reduce the incidence of recurrent VTE by approximately 90%. However, the 
impact of anticoagulant treatment together with antiplatelet treatment to prevent PE in MI 
patients needs to be weighed against the expected bleeding risk of combined treatment [35, 37-
39]. Alternatively, the transient nature of VTE risk after MI, may suggest that MI patients may 
benefit more from extended thromboprophylaxis with low-molecular weight heparins (LMWH) or 
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NOACs with an expected efficacy of 50-70% prevention of VTEs over the first 3-6 months [40, 
41]. 
Major strengths of our study include the prospective design, the large number of 
participants recruited from a general population, the long-term follow-up, the wide age 
distribution, the updated confounder information, and the validated events of VTE and MI. As 
many cardiovascular risk factors are modifiable, some participants’ individual risk profile may 
change during follow-up, leading to regression dilution bias and an underestimation of the 
associations. However, an advantage in our study is the repeated measurements of subject 
characteristics during follow-up. Due to this, we may to a greater extent explore the real effect of 
cardiovascular risk factors on the outcomes during follow-up, resulting in more reliable risk 
estimates than in a traditional cohort study. Yet, our study has some potential limitations. In a 
cohort study, non-response bias is a possible limitation. Those who participate in cohort studies 
tend to be healthier and more interested in their health than the general population. Our 
estimated incidence may therefore be lower than the true incidence. Further, the low number of 
both exposure and outcome events in the present cohort may lead to low statistical power to 
assess the potential impact of MI on the risk of VTE, particularly in subgroup-analyses. 
In conclusion, the present cohort study implies that first-lifetime MI is associated with increased 
risk of VTE, and particularly PE. The transient nature of the VTE risk after MI suggests that 
direct or indirect causal mechanisms related to the MI event itself are primarily responsible for 
the observed association. We found that 6.2% of the VTE events in the population could be 
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Table 1. Baseline characteristics of participants without and with MI (n=29506). The Tromsø 
Study 1994-2010. 
 No MI (n=27614) MI (n=1892) 
Age, y 45±14 62±13 
Sex (male) 45.9 (12675) 61.0 (1154) 
BMI (kg/m2) 25.2±3.9 26.6±4.1 
Total cholesterol (mmol/L) 5.90±1.27 6.92±1.28 
HDL (mmol/L) 1.50±0.41 1.41±0.40 
Triglycerides (mmol/L) 1.51±1.02 1.95±1.18 
Systolic blood pressure (mmHg) 132±19  152±24 
Diastolic blood pressure (mmHg) 77±12 87±14 
Hypertension* 31.5 (8700) 70.7 (1337) 
Hypercholesterolemia†  30.5 (8429) 63.0 (1192) 
Smoking ‡ 35.6 (9803) 41.2 (780) 
Physical activity § 33.4 (9210) 20.0 (380) 
Education║ 34.1 (9406) 12.2 (231) 
Self-reported diabetes mellitus 1.5 (401) 6.3 (120) 
Values are % (n) or mean±SD. MI indicates myocardial infarction and BMI body mass index 
*Mean systolic/diastolic blood pressure ≥140/≥90 mm Hg, use of antihypertensives, or self-
reported hypertension.  
†Total cholesterol ≥6.5 mmol/L, use of lipid-lowering drugs, or self-reported 
hypercholesterolemia. 
‡Self-reported daily smoking, yes/no. 
§≥1hours of moderate or hard physical activity per week, yes/no. 
║>10 years of education.  
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Table 2. Characteristics of Venous Thromboembolism Events (n=699). The Tromsø Study 1994-
2010. 
  % (n) 
Clinical characteristics  
 Deep vein thrombosis 57.9 (405) 
 Pulmonary embolism 42.1 (294) 
 Provoked 51.2 (358) 
 Unprovoked 48.8 (341) 
Clinical risk factors  
 Oestrogen*† 5.9 (41) 
 Pregnancy/puerperium* 0.9 (6) 
 Heredity‡ 3.4 (24) 
Provoking factors  
 Surgery 15.5 (108) 
 Trauma 7.9 (55) 
 Cancer 24.0 (168) 
 Immobility§ 18.3 (128) 
 Other|| 4.9 (34) 
*Only women included in the analysis. 
†Current or previous use of hormone replacement therapy or oral contraceptives. 
‡Myocardial infarction in a first-degree relative before 60 years of age. 
§Bed rest>3 days, journeys of>4 h by car, boat, train or air within the last 14 days, or other types 
of immobilization. 




Table 3. Incidence Rates and Hazard Ratios of VTE, DVT and PE according to MI exposure. The Tromsø Study 1994-2010. 










Total VTE        
   No MI 354865 652 1.8 (1.7-2.0) Reference Reference Reference 
   MI 7062 47 6.7 (5.0-8.9) 1.49 (1.10-2.01) 1.41 (1.04-1.92) 1.51 (1.09-2.11) 
DVT       
   No MI 354865 383 1.1 (1.0-1.2) Reference Reference Reference 
   MI 7062 22 3.1 (2.1-4.7) 1.25 (0.81-1.93) 1.17 (0.75-1.83) 1.36 (0.86-2.15) 
PE       
   No MI 354865 269 0.8 (0.7-0.9) Reference Reference Reference 
   MI 7062 25 3.5 (2.4-5.2) 1.80 (1.18-2.73) 1.71 (1.12-2.60) 1.72 (1.07-2.79) 
CI indicates confidence interval; DVT deep vein thrombosis; HR hazard ratio; IR incidence rate; MI myocardial infarction; PE 
pulmonary embolism; and VTE venous thromboembolism. 
 *Per 1000 persons-years. 
†Model 1: Age as timescale, adjusted for sex. 
‡Model 2: Model 1+body mass index. 
§Model 3: Model 2+systolic blood pressure, diabetes mellitus, HDL-cholesterol, smoking, physical activity, and education level
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Table 4. Incidence Rates and Hazard Ratios for VTE, DVT and PE according to MI exposure by the presence of predisposing factors. 
The Tromsø Study 1994-2010. 
 Person-years VTE Events Crude IR(95% CI)* Model 1† 
HR(95% CI) 
Model 2‡ 
HR(95% CI)  
Model 3§ 
HR(95% CI) 
Provoked VTE        
   No MI 354865 331 0.9 (0.8-1.0) Reference Reference Reference 
   MI 7062 27 3.8 (2.6-5.6) 1.65 (1.11-2.46) 1.63 (1.09-2.42) 1.83 (1.21-2.79) 
Unprovoked VTE        
   No MI 354865 321 0.9 (0.8-1.0) Reference Reference Reference 
   MI 7062 20 2.8 (1.8-4.4) 1.32 (0.83-2.09) 1.19 (0.75-1.91) 1.16 (0.67-2.00) 
Provoked DVT       
   No MI 354865 216 0.6 (0.5-0.7) Reference Reference Reference 
   MI 7062 15 2.1 (1.3-3.5) 1.44 (0.85-2.47) 1.45 (0.85-2.48) 1.59 (0.91-2.76) 
Unprovoked DVT       
   No MI 354865 167 0.5 (0.4-0.5) Reference Reference Reference 





Table 4. Continued 






Provoked PE       
   No MI 354865 115 0.3 (0.3-0.4) Reference Reference Reference 
   MI 7062 12 1.7 (1.0-3.0) 2.00 (1.09-3.67) 1.91 (1.04-3.50) 2.29 (1.20-4.37) 
Unprovoked PE       
   No MI 354865 154 0.4 (0.4-0.5) Reference Reference Reference 
   MI 7062 13 1.8 (1.1-3.2) 1.65 (0.92-2.94) 1.56 (0.88-2.79) 1.29 (0.62-2.67) 
CI indicates confidence interval; DVT deep vein thrombosis; HR hazard ratio; IR incidence rate; MI myocardial infarction; PE 
pulmonary embolism; and VTE venous thromboembolism. 
 *Per 1000 persons-years. 
†Model 1: Age as timescale, adjusted for sex. 
‡Model 2: Model 1+body mass index. 
§Model 3: Model 2+systolic blood pressure, diabetes mellitus, HDL-cholesterol, smoking, physical activity, and education level
 
 
Table 5. Incidence Rates and Hazard Ratios for VTE and PE according to time after MI. The Tromsø Study 1994-2010.  










VTE        
No MI 354865 652 1.8 (1.7-2.0) Reference Reference Reference 
<6 months 601 11 18.3 (10.1-33.0) 4.38  (2.41-7.98) 4.26 (2.34-7.75) 4.82 (2.57-9.05) 
0.5-1 year 556 4 7.2 (2.7-19.2) 1.72 (0.64-4.61) 1.68 (0.63-4.49) 2.10 (0.78-5.62) 
1-3 years 1880 9 4.8 (2.5-9.2) 1.14 (0.59-2.20) 1.10(0.57-2.13) 1.20 (0.60-2.42) 
3-5 year 1428 9 6.3 (3.3-12.1) 1.45 (0.75-2.81) 1.40 (0.72-2.71) 1.56 (0.77-3.14) 
>5 years 2598 14 5.4 (3.2-9.1) 1.11 (0.65-1.89) 1.00 (0.58-1.74) 0.90 (0.46-1.74) 
DVT       
No MI 354865 383 1.1 (1.0-1.2) Reference Reference Reference 
<6 months 601 3 5.0 (1.6-15.5) 2.08 (0.67-6.52) 2.05 (0.66-6.42) 2.41 (0.77-7.54) 
0.5-1 year 556 1 1.8 (0.3-12.8) 0.76 (0.11-5.43) 0.75 (0.11-5.37) 0.89 (0.13-6.38) 
1-3 years 1880 4 2.1 (0.8-5.7) 0.89 (0.33-2.39) 0.88 (0.33-2.36) 1.03 (0.38-2.77) 
3-5 year 1428 7 4.9 (2.3-10.3) 2.04 (0.96-4.32) 1.99 (0.94-4.23) 1.14 (1.14-5.15) 
>5 years 2598 7 2.7 (1.3-5.7) 1.00 (0.47-2.13) 0.85 (0.38-1.90) 0.89 (0.37-2.16) 
 
 
Table 5 continued 











      
No MI 354865 269 0.8 (0.7-0.9) Reference Reference Reference 
<6 months 601 8 13.3 (6.7-26.6) 7.46 (3.67-15.17) 7.13 (3.51-14.48) 8.49 (4.00-18.17) 
0.5-1 year 556 3 5.4 (1.7-16.7) 2.98 (0.95-9.32) 2.83 (0.90-8.85) 3.78 (1.20-11.89) 
1-3 years 1880 5 2.7 (1.1-6.4) 1.46 (0.60-3.54) 1.38 (0.57-3.35) 1.45 (0.53-3.91) 
3-5 years 1428 2 1.4 (0.4-5.6) 0.72 (0.18-2.92) 0.68 (0.17-2.76) 0.44 (0.06-3.18) 
>5 years 2598 7 2.7 (1.3-5.7) 1.24 (0.58-2.64) 1.18  (0.56-2.52) 0.90 (0.33-2.45) 
 
CI indicates confidence interval; DVT deep vein thrombosis; HR hazard ratio; IR incidence rate; MI myocardial infarction; PE pulmonary 
embolism; and VTE venous thromboembolism. 
*Per 1000 persons-years. 
†Model 1: Age as timescale, adjusted for sex. 
‡Model 2: Model 1+body mass index. 
§Model 3: Model 2+systolic blood pressure, diabetes mellitus, HDL-cholesterol, smoking, physical activity, and education level. 
